Primary imputation methods impact efficacy results in hidradenitis suppurativa clinical trials - 23/07/20
Doi : 10.1016/j.jaad.2020.03.078
John W. Frew, MBBS(Hons), MMed, MSc ⁎ 
Laboratory of Investigative Dermatology, Rockefeller University, New York, New York
∗Correspondence to: John W. Frew, MBBS(Hons), MMed, MSc, Laboratory of Investigative Dermatology, Rockefeller University, 1230 York Ave, New York, NY, 10065Laboratory of Investigative DermatologyRockefeller University1230 York AveNew YorkNY10065
| Funding sources: Supported in part by grant no. UL1 TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health Clinical and Translational Science Award program. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 2
P. 663-665 - août 2020 Retour au numéro
Article précédent
- Risk of malignancy in histiocytoid Sweet syndrome: A systematic review and reappraisal
- Roger Haber, Joelle Feghali, Maria El Gemayel
- Efficacy of oral zinc and nicotinamide as maintenance therapy for mild/moderate hidradenitis suppurativa: A controlled retrospective clinical study
- Elisa Molinelli, Valerio Brisigotti, Anna Campanati, Claudia Sapigni, Alfredo Giacchetti, Carlo Cota, Annamaria Offidani
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?